S&P 500

5.303,27

0,12%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

0QDU

Abliva Ab (0QDU)

Abliva Ab

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:LSE:0QDU

1

Data	Hora	Fonte	Título	Código	Companhia
19/02/2020	05:03	PR Newswire (US)	NeuroVive Pharmaceutical AB Year End Report January - December 2019	LSE:0QDU	Abliva Ab
20/12/2019	11:44	PR Newswire (US)	NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study	LSE:0QDU	Abliva Ab
16/12/2019	07:21	PR Newswire (US)	NeuroVive Announces Settlement in Dispute With CicloMulsion AG	LSE:0QDU	Abliva Ab
20/11/2019	05:04	PR Newswire (US)	NeuroVive Pharmaceutical AB Interim Report January - September 2019	LSE:0QDU	Abliva Ab
21/08/2019	03:55	PR Newswire (US)	NeuroVive Pharmaceutical AB Interim Report January - June 2019	LSE:0QDU	Abliva Ab
20/08/2019	08:23	PR Newswire (US)	Save the Date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019	LSE:0QDU	Abliva Ab
27/07/2019	08:38	PR Newswire (US)	NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation	LSE:0QDU	Abliva Ab
04/07/2019	09:46	PR Newswire (US)	NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study	LSE:0QDU	Abliva Ab
21/05/2019	03:45	PR Newswire (US)	NeuroVive Pharmaceutical AB Interim Report January - March 2019	LSE:0QDU	Abliva Ab
10/05/2019	03:48	PR Newswire (US)	NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA	LSE:0QDU	Abliva Ab
25/03/2019	06:48	PR Newswire (US)	NeuroVive Pharmaceutical AB Publishes 2018 Annual Report	LSE:0QDU	Abliva Ab
07/03/2019	05:07	PR Newswire (US)	NeuroVive Receives SEK 28.2 Million in a Directed New Share Issue	LSE:0QDU	Abliva Ab
21/02/2019	04:52	PR Newswire (US)	NeuroVive Enters Commercial Partnership With Oroboros Instruments on Mitochondrial Medicine Research Compounds	LSE:0QDU	Abliva Ab
15/11/2018	09:25	PR Newswire (US)	NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders	LSE:0QDU	Abliva Ab
31/10/2018	05:07	PR Newswire (US)	NeuroVive Today Announces That the Subscription Period for Warrants of Series 2018:1 Will Begin on Thursday, November 1	LSE:0QDU	Abliva Ab
04/10/2018	03:50	PR Newswire (US)	NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBI	LSE:0QDU	Abliva Ab
11/12/2017	08:41	PR Newswire (US)	NeuroVive Reports Promising Progress in its Clinical Project for Genetic Mitochondrial Diseases, KL1333	LSE:0QDU	Abliva Ab